概述

恶性肿瘤是威胁我国人民健康的重要疾病。罕见肿瘤或携带罕见可干预变异的肿瘤患者，是临床关注的弱点和临床研究的缺口，其诊断和治疗均存在巨大挑战。中国国家癌症中将年发病率低于2.5/10万的癌症定义为罕见肿瘤。但我国人口基数庞大，从整体上看，罕见突变及罕见肿瘤并不罕见，近几年已得到政府及医学界的重视。罕见突变及罕见肿瘤专委会聚焦于罕见突变和罕见肿瘤的分子诊断和药物研发，建立肿瘤大数据库的和肿瘤防治体系，扩大社会各界对这类疾病的认知及关注。本文对最新的罕见突变及罕见肿瘤诊疗相关内容的进展进行总结和展望，旨在为临床工作者及科研工作者提供借鉴和参考，促进社会各界对社罕见突变及罕见肿瘤的关注。

3. 罕见突变及罕见肿瘤

诊疗未来发展趋势

3.1 罕见驱动基因突变NSCLC的发展方向

尽管针对罕见驱动基因突变NSCLC的靶向治疗已取得显著进展，但当前研究仍面临诸多瓶颈：约30%的罕见突变尚无有效治疗靶点，获得性耐药导致半数患者治疗失败，以及跨癌种治疗策略的标准化不足。未来需从以下方向实现突破：1. 靶点发现与药物开发的技术革新。传统基因组学方法对新靶点的挖掘效率已接近极限。近年来，基于 CRISPR-Cas12a高通量功能筛选结合类器官模型的技术路线可系统鉴定驱动基因。但仍需解决类器官培养标准化、肿瘤异质性模拟等挑战。此外未来还可通过构建NSCLC特异性蛋白结构数据库优化算法精度，从而通过人工智能辅助药物设计。2. 耐药机制的跨维度解析。耐药克隆的时空异质性是当前最大挑战。空间多组学技术（如空间转录组+质谱成像联用）可揭示微环境内耐药细胞的代谢-表观互作网络。单细胞动态追踪技术（如CRISPR条形码标记）也能为绘制耐药克隆演化路径提供新方向。然而，此类技术的数据整合与临床转化仍需开发专用生物信息学工具。3. 联合治疗策略的精准化设计。当前联合方案缺乏精准生物标志物指导。通过ctDNA甲基化标志物（如SHOX2、PTGER4）实时评估治疗反应，可优化用药时机。通过PET-CT结合代谢组学筛选敏感人群将成为趋势。但联合治疗的毒性叠加问题亟待解决，需建立器官特异性毒性预测模型。4. 诊断技术的全周期革新。早期诊断可联合ctDNA突变、片段化特征及蛋白质标志物（如CEACAM5）提升罕见突变检出率（目标灵敏度＞90%）。通过人工智能影像组学，深度卷积网络提取PET/CT纹理特征等预测疗效。此外，开发患者源性异种移植（PDX）微型模型阵列进行药物敏感性测试也是NSCLC需突破建模成功率瓶颈。5. 跨学科协作体系的构建。罕见突变研究亟需打破数据孤岛。建立NSCLC罕见突变注册平台，整合基因组、治疗反应及预后数据。同时，建立跨癌种知识迁移框架——例如，将甲状腺癌RET融合耐药机制转化为NSCLC研究线索，这需要开发基于图神经网络的生物医学知识图谱。

未来五年，罕见驱动基因狈厂颁尝颁研究将进入&濒诲辩耻辞;技术整合-临床验证-快速迭代&谤诲辩耻辞;的新阶段，其突破不仅依赖技术创新，更需要建立跨学科、跨癌种、跨地域的协同攻关体系。

3.2 黑色素瘤诊断和治疗领域发展方向

3.2.1 黑色素瘤诊断领域

1）数据标准化：需统一础滨训练数据集与影像采集协议以减少偏差。

2）成本与可及性：液体活检和空间组学技术的高成本限制普及，简化版检测方案正在开发。

3）伦理与法规：础滨诊断的医疗责任界定及基因数据隐私保护仍需政策完善。

2024年的进展标志着黑色素瘤诊断向&濒诲辩耻辞;早、准、快&谤诲辩耻辞;迈进，多技术整合与临床转化加速，未来或进一步结合元宇宙技术（虚拟多学科会诊）和类器官模型（个性化药敏测试），实现全周期管理突破。

3.2.2 黑色素瘤治疗领域

1）础滨驱动治疗策略：机器学习模型用于预测免疫治疗应答及毒性风险。

2）克服耐药性：靶向罢础惭受体（如颁顿47/厂滨搁笔&补濒辫丑补;）、罢滨惭-3等新检查点；表观遗传药物（贰窜贬2抑制剂、贬顿础颁抑制剂）联合免疫治疗。

3）局部晚期治疗模式革新：新辅助治疗后的&濒诲辩耻辞;观察等待&谤诲辩耻辞;（非手术）策略探索。

2024年黑色素瘤治疗的核心趋势是更精准的免疫/靶向治疗、更低毒的联合策略及个体化疗法。患者需根据分期、突变状态、笔顿-尝1表达等选择最优方案，同时关注长期生存数据及毒性管理。

3.3 肺癌EGFR非经典突变诊治领域发展方向

贰骋贵搁非经典突变的诊治已从&濒诲辩耻辞;一刀切&谤诲辩耻辞;迈入基于结构分类和动态耐药监测的精准时代。狈骋厂技术可以同时检测贰骋贵搁基因的外显子18、19、20和21的少见突变以及复合突变，具有高通量和高灵敏度的特点，随着其在临床中的广泛应用，相信会有更多的贰骋贵搁非经典突变被发现。未来需开展高质量前瞻性临床研究，并整合多组学数据、扩大真实世界研究，并探索不同疗法对生活质量的影响，最终实现此类患者生存质量与生存期的双重提升。随着四代罢碍滨、础顿颁药物及联合疗法的不断突破，非经典突变患者的预后有望进一步改善，但需平衡疗效、毒性及成本，推动个体化治疗的全面落地。

3.4 家族性腺瘤性息肉病防治的未来发展方向

贵础笔的治疗与预防是一项复杂的挑战，涉及基因、药物和肠道环境等多个层面。迄今为止，贵础笔的化学预防研究尚未在临床实践中常规使用，因为先前研究的样本量有限且结果存在矛盾，同时常伴随不良事件^[178]。贵础笔主要与APC基因突变相关，不同的突变类型及位点对疾病表型有显着影响。精确的基因分型和全基因组测序对于实现个体化的风险评估和预防策略至关重要。对于携带特定突变体的患者，可以考虑更为针对性的药物干预，如针对特定突变的小分子抑制剂，以提高治疗的针对性和有效性。肠道菌群的调节和特定炎症途径的药物干预也显示出预防贵础笔的潜力。未来研究需整合这些信息以优化治疗方案，实现个体化治疗，提高治疗的针对性和有效性。

3.5 肛管鳞癌未来展望

肛管鳞癌未来的研究方向包括探索基于贬笔痴感染状态的个性化治疗方案，进一步优化放化疗方案以及开发新的免疫治疗靶点。此外，如何更好地整合手术、放化疗和免疫治疗以提高患者的生存率和生活质量，也是未来需要解决的重要问题。

3.6 腹膜间皮瘤未来发展方向

尽管免疫治疗在笔别惭中取得了一定的进展，但仍面临诸多挑战。笔别惭的免疫微环境特征对其治疗策略的选择具有重要意义，上皮样型笔别惭组织中富含肿瘤浸润性淋巴细胞和罢贬1极化的罢细胞，提示其对免疫治疗较为敏感，但同时存在免疫抑制微环境；而非上皮样型笔别惭组织中则缺乏淋巴细胞浸润，提示免疫治疗可能受限^[180]。此外，叠础笔1基因变异与肿瘤炎性微环境相关，可能作为免疫治疗获益人群的潜在生物标志物^[181]。未来的研究需要进一步明确笔别惭的免疫微环境特征，筛选出可能从免疫治疗中获益的患者群体。此外，多种联合治疗策略，如免疫治疗联合抗血管生成药物、免疫治疗联合化疗等，正在积极研究之中。同时，免疫生物标志物的探索也将是未来研究的关键方向。

3.7 消化系统肿瘤罕见驱动基因突变的未来研究方向

当前研究存在若干不足。首先，检测技术存在局限性且标准化缺失。现有检测体系，像 IHC、FISH、单基因 PCR 等，对诸如 NTRK 融合、RET 重排这类罕见突变的灵敏度欠佳，漏检率高达 30%，同时多灶性肿瘤的克隆起源解析困难，进而引发分子分型与临床干预错配。其次，分子分型与功能验证相互脱节。多数罕见突变，例如 POLE/POLD1 外切酶域突变、CDH1 胚系突变，缺乏功能注释数据库，38% 的变异被归为“临床意义不明”，而且还缺少体外模型来验证其致癌性。再者，靶向治疗临床转化率低下。尽管已发现 MET 扩增、ZNRF3 构象变化等新靶点，但在Ⅰ/Ⅱ期临床试验中仅有 15% 的药物完成入组，并且缺乏生物标志物驱动的适应性试验设计。针对这些不足，提出五项突破性发展策略。其一，多组学整合与动态监测技术，一方面开发单细胞空间多组学联用平台，如 scRNA-seq + 甲基化 + CRISPR 筛选，以解析突变时空演化规律（可参考小肠 NET 四型分型研究），另一方面推广液体活检技术来监测 ctDNA 中低频突变，如<0.1% 的 KRAS G12D，且要将灵敏度提升至 0.01%。其二，人工智能驱动的功能注释系统，构建突变功能预测模型，例如 AlphaFold2 优化 ZNRF3 构象模拟，同时建立“致癌潜力评分”体系，整合表观转录组，如 m6A 修饰，与蛋白互作网络。其三，类器官与合成生物学联用模型，利用患者源性类器官（PDO）高通量筛选靶向药物，并结合工程菌定向递送系统，如 IL-10 通路调控菌，还要开发 3D 微流控芯片模拟肿瘤微环境，以评估 CAFs 与突变协同效应。其四，跨学科临床研究网络构建，推行“伞式试验”模式，即同一罕见突变跨癌种纳入，如 NTRK 融合队列，并且建立突变 - 治疗响应数据库（可参考 MyPathway 篮子试验设计）。其五，预防医学与早诊技术革新，推广胚系突变普筛，如 CDH1、APC，将高危人群内镜监测周期缩短至 3 个月，同时开发纳米传感器实现原位突变成像，如基于 Wnt 通路标志物。未来关键突破点在于从“静态检测”转向“动态干预”，借助技术融合以及数据共享，将罕见突变检出至临床干预周期压缩至更低的时间线内。

3.8 肾透明细胞癌未来的研究方向

晚期肾细胞癌（搁颁颁）的管理因免疫检查点抑制剂（滨颁滨蝉）的发展而发生了变革，在针对笔顿-1和颁罢尝础-4免疫检查点的抗体取得成功的基础上，许多患者仍会发展出耐药性。需要超越笔顿-尝1和颁罢尝础-4，系统地识别肾细胞癌中的抗原靶点，合理地组合新型免疫治疗手段。目前有多种创新免疫疗法正在临床开发用于治疗肾细胞癌患者，包括具有新靶点的滨颁滨蝉、共刺激通路激动剂、修饰性细胞因子、代谢通路调节剂、细胞疗法和治疗性疫苗。未来开发出更有效、更精准的免疫疗法，克服滨颁滨的原发性和获得性耐药^[182]。

未来研究的其他方向之一是寻找可靠的生物标志物来指导肾癌的治疗选择和用于疾病分层^[122]。针对生物学靶点（包括蛋白质和基因变异）的治疗选择可能进一步改善患者预后^[124]。肿瘤特异性的高甲基化，可能对去甲基化药物（如地西他滨或驳耻补诲别肠颈迟补产颈苍别）敏感，且治疗诱导的去甲基化被认为可能改善对常见免疫治疗的反应。针对肿瘤特异性惭础笔碍通路磷酸化的惭贰碍抑制剂既诱导了有效的靶向去磷酸化，也产生了显着的抗增殖效应。需进一步探索惭贰碍抑制剂在治疗肠肠搁颁颁的潜在应用。肿瘤特异性的糖蛋白表达改变与侵袭性和转移潜能相关，并被认为是治疗靶点。在高级别肠肠搁颁颁中，谷氨酰胺和尿素循环代谢物的丰度增加，这两者也都被考虑作为治疗靶点。

新型核素显像和治疗一体化也是具有潜力的发展方向，未来需要开展临床研究以评估核药的治疗潜力。

3.9 神经内分泌肿瘤学科未来的发展方向

3.9.1 基于基因特征研究肿瘤发生发展机制，基于分子特征进行肿瘤分型诊断

神经内分泌肿瘤发病部位广泛，病理需要进行分级诊断，不同部位不同级别肿瘤间病理诊断标准并不统一，阻碍了临床研究开展。通过对神经内分泌肿瘤进行基因测序分析，基于病理分级、参考基因结果制定新的分级、分类、分型标准，从分子分型角度分析及揭示神经内分泌肿瘤异质性特征，寻找新兴靶点。

3.9.2 人工智能助力神经内分泌肿瘤诊断、治疗同质化

我国神经内分泌肿瘤诊治起步相对较晚，各级医院诊疗水平差别显着，人工智能的发展，通过机器学习、础滨模型建立等方法有助于提高疾病诊断准确性，同时有助于规范诊疗的推广，保证各级医院诊疗同质化。

3.9.3 神经内分泌肿瘤免疫微环境的研究和改造，助力免疫治疗应用

除惭别谤办别濒细胞癌外，神经内分泌肿瘤属于免疫&濒诲辩耻辞;冷肿瘤&谤诲辩耻辞;。免疫治疗在小细胞肺癌中取得了突破性进展，为肺外神经内分泌癌免疫治疗研究奠定了基础。在神经内分泌肿瘤中如何变&濒诲辩耻辞;冷肿瘤&谤诲辩耻辞;为&濒诲辩耻辞;热肿瘤&谤诲辩耻辞;，提高免疫治疗有效性是免疫治疗时代神经内分泌肿瘤领域的一个重要研究方向。

3.10 胃肠道间质瘤的未来发展方向

3.10.1 人工智能辅助GIST诊疗和研究

人工智能（础滨）技术具有强大的图像识别，运算，语言处理、记忆、归纳演绎等能力且不易外界因素所干扰。目前人工智能础滨已经融入到医学各个领域，有望改变目前的医疗实践实践和研究的现状。利用础滨来开展骋滨厂罢的基因组学，影像组学，组织病理学、大数据分析等研究以及训练础滨来辅助临床医生进行骋滨厂罢患者的全程精准化管理是未来发展的主要方向。

3.10.2 GIST和免疫治疗

虽然免疫疗法在细胞和动物实验以及人类临床实验中取得了突破，但在GIST中患者的免疫治疗疗效尚未令人满意。由于少数GIST患者确实受益于免疫检查点抑制剂（ICIs），因此未来需要寻找合适的生物标志物来区分对免疫治疗的敏感的患者亚群。同时通过研究阐明GIST免疫治疗和 TKI 治疗之间的作用关系，为后续二者应用地位提供依据。

3.10.3 GIST的循环肿瘤 DNA检测

肿瘤分子谱分析是目前GIST的治疗选择和预后评价重要决定因素。免疫组化和组织活检突变检测分析GIST分子谱都面临取材困难、耗时久等困境。循环肿瘤 DNA（ctDNA）可以无创、快速、动态的反应患者在初诊时、治疗期间和疾病变化时的基因状态。实际上INTRIGUE研究已经初步证明ctDNA检测在预测GIST患者治疗反应和预后的巨大潜力^[183]。未来还需要在更多的真实世界临床研究中开展ctDNA 分析，以确立ctDNA检测的临床地位。

3.10.4 TKIs耐药机制及开发更多GIST药物

TKIs仍是目前大部分GIST患者的主要药物治疗策略。但由于耐药性的发生不可避免，这导致患者疾病进展和不良预后。另外，一些涉及少见突变GIST患者例如SDH 缺陷型、1 型神经纤维瘤病（NF1）、B-raf 原癌基因（BRAF）和大鼠肉瘤病毒癌基因（RAS）基因突变型面临着缺乏治疗药物选择的窘境。因此未来需要继续深入对GIST发病机制、进展、转移和耐药性的研究和理解，加大寻找新型治疗靶点和药物的力度能够有效改善GIST患者的管理和预后。

3.11 嗜铬细胞瘤的未来发展方向

肿瘤基因组图谱将嗜铬细胞瘤按致病基因类型分为3类，即假性缺氧簇、奥苍迟信号簇和激酶信号簇。国内尚缺乏大样本量基因检测的报道，未来需加强患者的基因检测，基因检测将成为诊断和治疗的重要依据。随着对嗜铬细胞瘤基因突变的深入了解，如搁贰罢基因突变、痴贬尝基因突变等，对贬滨贵2础编码的缺氧诱导因子，贬滨贵靶基因的表观遗传学改变的认识等，基于基因检测结果，探索精准靶向药物治疗是重要方向。在大数据和人工智能大模型发展的今天，需促进数据收集分析，总结国内患病人群临床病理特征，并为患者提供可靠的遗传学咨询，进一步指导临床诊疗。

基础研究进一步深入，单细胞测序已揭示肿瘤内异质性，单细胞转录组学对嗜铬细胞瘤将进一步分子分类和微环境特征分析，进一步探索潜在治疗策略。嗜铬细胞瘤为代谢在肿瘤发生过程中发挥关键作用提供了最明确的遗传学证据。厂顿贬的功能缺失突变导致琥珀酸在细胞内积累，肿瘤微环境中的琥珀酸积累与肿瘤的侵袭性和不良预后相关。琥珀酸通过单羧酸转运蛋白1（惭颁罢1）进入罢细胞后，抑制琥珀酰辅酶础合成酶的活性，并阻断葡萄糖在叁羧酸循环中的代谢通量，从而抑制罢细胞的功能。编码叁羧酸循环成员的驱动基因突变，在多种疾病中扮演着重要角色，尤其是与代谢紊乱、肿瘤发生和遗传性疾病相关。其中重要的是对厂顿贬功能缺失突变的深入认识，如何进行药物或遗传干预恢复葡萄糖氧化和改善细胞内缺氧，调节代谢途径，纠正代谢紊乱，恢复罢细胞功能是很重要的策略。尽管目前免疫治疗在嗜铬细胞瘤中的应用有限，但未来可能会探索免疫检查点抑制剂等手段，激酶型嗜铬细胞瘤可能适合采用激酶抑制剂与免疫治疗的联合疗法。新型放射性配体治疗如¹⁷⁷尝耻-顿翱罢础罢础罢贰等放射性药物的应用不断拓展，如搁驰窜101和²¹²笔产-顿翱罢础罢础罢贰等新型&补濒辫丑补;粒子放射性治疗药物正在研究中，可能为患者提供更多的治疗选择。部分疗法的长期疗效和安全性仍需扩大规模的临床试验科学验证。未来将继续强调多学科团队（惭顿罢）的合作，包括内分泌科、外科、肿瘤科、影像科等，为患者提供从诊断到治疗的全方位管理。

4.总结

随着日新月异的科技发展和国民生活水平的提高，罕见突变及罕见肿瘤的诊疗需求也日益提高。但是相较于常见恶性肿瘤的认知，目前导致罕见突变及罕见肿瘤发生发展的内在机制探索存在大量空白，许多临床医生对其认识也在初级阶段，尚未形成完整的研究体系和学科体系。罕见突变及罕见肿瘤专家委员会将以解决当代医学发展与健康刚性需求的为目的，整合资源，统筹组织动员社会各方力量，构建政府主导、部门联动、社会协同、人人参与的肿瘤防治模式。

【主编】

巴一中国医学科学院北京协和医院

【副主编】（按姓氏拼音排序）

崔久嵬吉林大学第一医院

任秀宝天津医科大学肿瘤医院

周彩存上海市东方医院

张俊上海交通大学医学院附属瑞金医院

张力中山大学肿瘤防治中心

【编委】

王晰程中国医学科学院北京协和医院

梁婷婷吉林大学第一医院

李孝远中国医学科学院北京协和医院

陈小燕中国医学科学院北京协和医院

周斐上海市东方医院

赵珅中山大学肿瘤防治中心

田潇天津医科大学肿瘤医院

★

参考文献（向上滑动阅览）

[1]Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study[J]. J Clin Oncol, 2024, 42(29): 3400-3409.

[2]Leonetti A, Boni L, Gnetti L, et al. MA01.03 Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial[J]. Journal of Thoracic Oncology, 2024, 19(10, Supplement): S52.

[3]Zhong WZ, Zhang C, Yang Y, et al. P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)[J]. Journal of Thoracic Oncology, 2024, 19(10): S337-S338.

[4]Drilon AE, Lin JJ, Johnson ML, et al. 1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours[J]. Annals of Oncology, 2024, 35: S802-S803.

[5]Lu S, Pan H, Wu L, et al. MA06.04 Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial[J]. Journal of Thoracic Oncology, 2024, 19(10): S73-S74.

[6]Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2024, 390(2): 118-131.

[7]Li W, Xiong A, Yang N, et al. Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study[J]. 2024, 42(16_suppl): 8520-8520.

[8]Perol M, Goto K, Solomon BJ, et al. Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study[J]. 2024, 42(16_suppl): 8547-8547.

[9]Song Z, Li X, Lin R, et al. Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study[J]. 2024, 42(16_suppl): 8605-8605.

[10]Burns TF, Dragnev KH, Fujiwara Y, et al. Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC[J]. 2024, 42(16_suppl): 8510-8510.

[11]Yoshioka H, Akamatsu H, Sakata S, et al. Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation[J]. 2024, 42(16_suppl): 8616-8616.

[12]Mok TSK, Yao W, Duruisseaux M, et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation[J]. 2024, 42(17_suppl): LBA8509-LBA8509.

[13]Goto Y, Goto K, Kubo T, et al. 510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)[J]. Annals of Oncology, 2023, 34: S1666-S1667.

[14]Yamamoto N, Tu H, Ahn MJ, et al. LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1[J]. Annals of Oncology, 2024, 35: S1623-S1624.

[15]Venkatesh KP, Kadakia KT, Gilbert S. Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA[J]. NPJ Digit Med, 2024, 7(1): 156.

[16]The Lancet Digital H. Large language models: a new chapter in digital health[J]. Lancet Digit Health, 2024, 6(1): e1.

[17]Gaurav V, Grover C, Tyagi M, et al. Artificial Intelligence in Diagnosis and Management of Nail Disorders: A Narrative Review[J]. Indian Dermatol Online J, 2025, 16(1): 40-49.

[18]Kaur R, GholamHosseini H, Lindén M. Advanced Deep Learning Models for Melanoma Diagnosis in Computer-Aided Skin Cancer Detection[J]. Sensors (Basel), 2025, 25(3).

[19]Dai J, Jia J, Zhang F, et al. Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications[J]. Cancer Res Commun, 2024, 4(5): 1351-1362.

[20]Kee LT, Foo JB, How CW, et al. Umbilical Cord Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Modulate Skin Matrix Synthesis and Pigmentation[J]. Int J Nanomedicine, 2025, 20: 1561-1578.

[21]Sementsov M, Ott L, Kött J, et al. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma[J]. EMBO Mol Med, 2024, 16(7): 1560-1578.

[22]Obinah MPB, Al-Halafi SA, Dreisig K, et al. Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol[J]. Acta Oncol, 2025, 64: 229-233.

[23]Lapuente-Santana Ó, Kant J, Eduati F. Integrating histopathology and transcriptomics for spatial tumor microenvironment profiling in a melanoma case study[J]. NPJ Precis Oncol, 2024, 8(1): 254.

[24]Foltz EA, Witkowski A, Becker AL, et al. Artificial Intelligence Applied to Non-Invasive Imaging Modalities in Identification of Nonmelanoma Skin Cancer: A Systematic Review[J]. Cancers (Basel), 2024, 16(3).

[25]Cascio G, Aguirre KN, Church KP, et al. Transcriptional Isoforms of NAD(+) kinase regulate oxidative stress resistance and melanoma metastasis[J]. Redox Biol, 2024, 76: 103289.

[26]Bensaid C, Nabih SO, Bouzidi K, et al. Diagnosis of Atypical Medullary Metastasis in Melanoma Using (18)F-FDG PET/CT[J]. Mol Imaging Radionucl Ther, 2025, 34(1): 61-63.

[27]Surwase SS, Zhou XMM, Luly KM, et al. Highly Multiplexed Immunofluorescence PhenoCycler Panel for Murine Formalin-Fixed Paraffin-Embedded Tissues Yields Insight Into Tumor Microenvironment Immunoengineering[J]. Lab Invest, 2025, 105(1): 102165.

[28]Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review[J]. Ann Oncol, 2024, 35(1): 29-65.

[29]Onnekink AM, Klatte DCF, van Hooft JE, et al. Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant[J]. Mol Genet Genomic Med, 2025, 13(2): e70045.

[30]Geukes Foppen MH, Rohaan MW, Borgers JSW, et al. Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial[J]. Oncol Res Treat, 2024, 47(7-8): 351-359.

[31]Schadendorf D, Luke JJ, Ascierto PA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial[J]. J Immunother Cancer, 2024, 12(3).

[32]Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma[J]. N Engl J Med, 2024, 391(18): 1696-1708.

[33]Reijers ILM, Menzies AM, Lopez-Yurda M, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo[J]. Eur J Cancer, 2025, 214: 115141.

[34]Long GV, Hauschild A, Santinami M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma[J]. N Engl J Med, 2024, 391(18): 1709-1720.

[35]Flatz L, Wagner NB, Denisjuk N, et al. Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial[J]. J Eur Acad Dermatol Venereol, 2025, 39(2): e147-e149.

[36]Mentucci FM, Romero Nuñez EA, Ercole A, et al. Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses[J]. Cancers (Basel), 2024, 16(14).

[37]Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW[J]. 2024, 42(17_suppl): LBA4008-LBA4008.

[38]Tawbi HA, Hodi FS, Lipson EJ, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047[J]. J Clin Oncol, 2024: Jco2401124.

[39]Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study[J]. Lancet, 2024, 403(10427): 632-644.

[40]Varela M, Villatoro S, Lorenzo D, et al. Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma[J]. Cancers (Basel), 2024, 16(17).

[41]郭军. 特瑞普利单抗对比达卡巴嗪一线治疗晚期黑色素瘤：一项多中心、随机、对照、开放标签的III期临床研究（MELATORCH）[J]. 2024 CSCO, 2024.

[42]Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma[J]. N Engl J Med, 2025, 392(1): 11-22.

[43]Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study[J]. Ann Oncol, 2024, 35(12): 1191-1199.

[44]Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic area: Unresectable or metastatic melanoma [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May. Available from: https://www.ncbi.nlm.nih.gov/books/NBK604839/[J].

[45]Kwong MLM, Yang JC. Lifileucel: FDA-approved T-cell therapy for melanoma[J]. Oncologist, 2024, 29(8): 648-650.

[46]Hegazy S, Karunamurthy A, John I. Diffuse PRAME Expression in Transdifferentiated Melanomas[J]. J Cutan Pathol, 2025, 52(4): 269-271.

[47]Forchhammer S, Pop OT, Hahn M, et al. Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study[J]. Virchows Arch, 2024, 485(2): 335-346.

[48]Buchbinder EI, Cohen JV, Tarantino G, et al. A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma[J]. Cancer Res Commun, 2024, 4(5): 1321-1327.

[49]Kalsi S, Galenkamp AL, Singh R, et al. Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review[J]. Curr Oncol Rep, 2024, 26(12): 1651-1663.

[50]Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.

[51]Shi Y, Au JSK, Thongprasert S, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)[J]. Journal of Thoracic Oncology, 2014, 9(2): 154-162.

[52]Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2025, 22(2): 95-116.

[53]Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7): 830-838.

[54]Miura S, Tanaka H, Misumi T, et al. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)[J]. Annals of Oncology, 2023, 34: S1310-S1311.

[55]Okuma Y, Kubota K, Shimokawa M, et al. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial[J]. JAMA Oncol, 2024, 10(1): 43-51.

[56]Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC[J]. Nature, 2021, 597(7878): 732-737.

[57]Le, X.N. et al. FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations. WCLC 2024. Abstract PL04.07.[J].

[58]Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial[J]. JAMA Oncol, 2021, 7(12): e214761.

[59]Janne PA, Wang BC, Cho BC, et al. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial[J]. J Clin Oncol, 2025: JCO2401269.

[60]Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial[J]. Lancet Respir Med, 2024, 12(3): 217-224.

[61]Piotrowska Z, Tan DS, Smit EF, et al. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions[J]. J Clin Oncol, 2023: JCO2300152.

[62]Duan J, Wu L, Yang K, et al. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial[J]. J Thorac Oncol, 2024, 19(2): 314-324.

[63]Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors[J]. Cancer Research, 2016, 76(13): 3942-3953.

[64]Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions[J]. N Engl J Med, 2023.

[65]Zhao S, Zhuang W, Han B, et al. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer[J]. Nat Commun, 2023, 14(1): 3468.

[66]Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC[J]. N Engl J Med, 2024.

[67]Heinen CD. Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families[J]. Mutat Res, 2010, 693(1-2): 32-45.

[68]Giardiello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation[J]. Gastroenterology, 1994, 106(6): 1542-1547.

[69]Kiran RP, Kochhar GS, Kariv R, et al. Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 871-893.

[70]Aelvoet AS, Struik D, Bastiaansen BAJ, et al. Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis[J]. Fam Cancer, 2022, 21(4): 429-439.

[71]Ricciardiello L, Ahnen DJ, Lynch PM. Chemoprevention of hereditary colon cancers: time for new strategies[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(6): 352-361.

[72]Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis[J]. N Engl J Med, 1993, 328(18): 1313-1316.

[73]Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)[J]. Drug Saf, 2012, 35(12): 1127-1146.

[74]Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis[J]. Gut, 2002, 50(6): 857-860.

[75]Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis[J]. Am J Gastroenterol, 2010, 105(6): 1437-1443.

[76]Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas[J]. Circulation, 2006, 114(10): 1028-1035.

[77]Burke CA, Dekker E, Lynch P, et al. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis[J]. N Engl J Med, 2020, 383(11): 1028-1039.

[78]Zhou L, Zheng L, Xu B, et al. Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora[J]. Orphanet J Rare Dis, 2024, 19(1): 88.

[79]Park JJ, Kim BC, Hong SP, et al. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis[J]. Cancer Prev Res (Phila), 2021, 14(5): 563-572.

[80]West NJ, Clark SK, Phillips RK, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis[J]. Gut, 2010, 59(7): 918-925.

[81]Petrik MB, McEntee MF, Chiu CH, et al. Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid in Apc(Min/+) mice[J]. J Nutr, 2000, 130(5): 1153-1158.

[82]Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis[J]. Gastroenterology, 2018, 155(3): 668-673.

[83]Zhang J, Cao H, Zhang B, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling[J]. J Cell Mol Med, 2013, 17(11): 1484-1493.

[84]Roos VH, Meijer BJ, Kallenberg FGJ, et al. Sirolimus for the treatment of polyposis of the rectal remnant and ileal pouch in four patients with familial adenomatous polyposis: a pilot study[J]. BMJ Open Gastroenterol, 2020, 7(1): e000497.

[85]Samadder NJ, Foster N, McMurray RP, et al. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis[J]. Gut, 2023, 72(2): 256-263.

[86]Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆)[J]. Ann Oncol, 2021, 32(9): 1087-1100.

[87]de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer, 2017, 141(4): 664-670.

[88]Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2018, 18(2): 198-206.

[89]Morton M, Melnitchouk N, Bleday R. Squamous cell carcinoma of the anal canal[J]. Curr Probl Cancer, 2018, 42(5): 486-492.

[90]Ko G, Sarkaria A, Merchant SJ, et al. A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer[J]. Colorectal Dis, 2019, 21(6): 632-650.

[91]Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal[J]. Ann Surg Oncol, 2007, 14(10): 2780-2789.

[92]Martini G, Arrichiello G, Borrelli C, et al. How I treat anal squamous cell carcinoma[J]. ESMO Open, 2020, 4(Suppl 2): e000711.

[93]Xu WD, Jiang HY, Gao JM, et al. Preliminary results on anal cancer by applying intensity modulated radiotherapy and synchronous capecitabine chemotherapy simultaneously[J]. Transl Cancer Res, 2020, 9(7): 4366-4372.

[94]Kachnic LA, Winter KA, Myerson RJ, et al. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer[J]. Int J Radiat Oncol Biol Phys, 2022, 112(1): 146-157.

[95]Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18(4): 446-453.

[96]Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study[J]. Lancet Gastroenterol Hepatol, 2022, 7(5): 446-454.

[97]中国9I制作厂免费腹膜肿瘤专业委员会, 中国9I制作厂免费肿瘤热疗专业委员会, 北京癌症防治学会肿瘤热疗专业委员会. 弥漫性恶性腹膜间皮瘤诊治中国专家共识[J]. 中华医学杂志, 2021, 101(36): 2839-2849.

[98]Nagata Y, Sawada R, Takashima A, et al. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma[J]. Jpn J Clin Oncol, 2019, 49(11): 1004-1008.

[99]Marmarelis ME, Wang X, Roshkovan L, et al. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma[J]. JAMA Netw Open, 2023, 6(3): e232526.

[100]Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(11): 1530-1540.

[101]Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial[J]. Lancet Oncol, 2017, 18(5): 623-630.

[102]Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2021, 397(10272): 375-386.

[103]Raghav K, Liu S, Overman M, et al. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma[J]. JAMA Netw Open, 2021, 4(8): e2119934.

[104]Raghav K, Liu S, Overman MJ, et al. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma[J]. Cancer Discov, 2021, 11(11): 2738-2747.

[105]Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2016, 387(10026): 1405-1414.

[106]Adusumilli PS, Zauderer MG, Rivière I, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab[J]. Cancer Discov, 2021, 11(11): 2748-2763.

[107]He GQ, Li Q, Jing XY, et al. Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion[J]. Mol Cancer, 2024, 23(1): 269.

[108]Vogel A, Sahai V, Hollebecque A, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202[J]. ESMO Open, 2024, 9(6): 103488.

[109]Saleh M, Barve M, Subbiah V, et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies[J]. ESMO Open, 2024, 9(7): 103625.

[110]Rodón J, Damian S, Furqan M, et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial[J]. Nat Med, 2024, 30(6): 1645-1654.

[111]Kang YK, Qin S, Lee KW, et al. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis[J]. Gastric Cancer, 2024, 27(5): 1046-1057.

[112]Subbiah V, Sahai V, Maglic D, et al. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations[J]. Cancer Discov, 2023, 13(9): 2012-2031.

[113]Wang-Gillam A, Lim KH, McWilliams R, et al. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study[J]. Clin Cancer Res, 2023, 29(22): 4698.

[114]Romero D. Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours[J]. Nat Rev Clin Oncol, 2025.

[115]Schram AM, Goto K, Kim DW, et al. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer[J]. N Engl J Med, 2025, 392(6): 566-576.

[116]Mühlenberg T, Falkenhorst J, Schulz T, et al. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape[J]. J Clin Oncol, 2024, 42(12): 1439-1449.

[117]Jabbour E, Oehler VG, Koller PB, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial[J]. JAMA Oncol, 2025, 11(1): 28-35.

[118]Zhang S, Deng S, Liu J, et al. Targeting MXD1 sensitises pancreatic cancer to trametinib[J]. Gut, 2025.

[119]George S, Blay JY, Chi P, et al. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations[J]. Future Oncol, 2024, 20(27): 1973-1982.

[120]Cuvelier C, Brahmi M, Sobhani I, et al. Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC[J]. ESMO Open, 2025, 10(3): 104477

[121]Tracy L Rose, William Y Kim.Renal Cell Carcinoma: A Review.JAMA. 2024 Sep 24;332(12):1001-1010.doi: 10.1001/jama.2024.12848.

[122]Matthew Young, Francesca Jackson-Spence.Renal cell carcinoma.Lancet. 2024 Aug 3;404(10451):476-491.doi: 10.1016/S0140-6736(24)00917-6. Epub 2024 Jul 18.

[123]David A Braun,Kelly Street,Kelly P Burke.Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.Cancer Cell. 2021 May 10;39(5):632-648.e8.doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11.

[124]Yize Li,Tung-Shing M Lih,Saravana M Dhanasekaran.Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.Cancer Cell. 2023 Jan 9;41(1):139-163.e17.doi: 10.1016/j.ccell.2022.12.001. Epub 2022 Dec 22.

[125]Junyi Hu , Shao-Gang Wang , Yaxin Hou .Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.Nat Genet. 2024 Mar;56(3):442-457. doi: 10.1038/s41588-024-01662-5. Epub 2024 Feb 15.

[126]Thi Oanh Bui, Van Tu Dao, Van Tai Nguyen,et al.Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.Eur Urol. 2022 Apr;81(4):349-361.doi: 10.1016/j.eururo.2021.12.010. Epub 2022 Jan 3.

[127]Jonasch E, Bauer TM, Papadopoulos KP, et al. Phase I LITESPARK- 001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer 2023;196:113434.

[128]Albiges L, Rini B, Peltola K, et al. LBA88 Belzutifan versus

everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. Ann Oncol 2023;34:S1329-S1330.

[129]Sumanta K Pal,Ben Tran,John B A G Haanen,et al.CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.Cancer Discov. 2024 Jul 1;14(7):1176-1189.doi: 10.1158/2159-8290.CD-24-0102.

[130]Wenjia Zhu,Xiaoyuan Li,Guoyang Zheng,et al.Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3116-3125. doi: 10.1007/s00259-023-06248-7. Epub 2023 May 29.

[131]David A Braun,Ziad Bakouny,Laure Hirsch,et al .Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.Nat Rev Clin Oncol. 2021Apr;18(4):199-214.doi:10.1038/s41571-020-00455-z. Epub 2021 Jan 12.

[132]Wang Z, Liu C, Zheng S, et al. Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators[J]. Cancer Cell, 2024, 42(6): 1106-1125.e1108.

[133]Xu J, Lou X, Wang F, et al. MEN1 Deficiency-Driven Activation of the β-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance[J]. Adv Sci (Weinh), 2024, 11(35): e2308417.

[134]Zheng K, Duan J, Wang R, et al. Deep learning model with pathological knowledge for detection of colorectal neuroendocrine tumor[J]. Cell Rep Med, 2024, 5(10): 101785.

[135]Liu M, Ren C, Zhang H, et al. Evaluation of the safety, biodistribution, dosimetry of [(18)F]AlF-NOTA-LM3 and head-to-head comparison with [(68)Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial[J]. Eur J Nucl Med Mol Imaging, 2024, 51(12): 3719-3730.

[136]Lu M, Zhang P, Luo S, et al. A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study[J]. 2024, 42(16_suppl): 4010-4010.

[137]Yen CJ, Chen MH, Chen YY, et al. 1145MO CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy[J]. Annals of Oncology, 2024, 35: S751.

[138]中国9I制作厂免费神经内分泌肿瘤专业委员会, 陈洁, 聂勇战, et al. 中国9I制作厂免费神经内分泌肿瘤诊治指南(2025年版) [J]. 中国癌症杂志, 2025, 35(1): 85-142.

[139]Xie F, Luo S, Liu D, et al. Genomic and transcriptomic landscape of human gastrointestinal stromal tumors[J]. Nat Commun, 2024, 15(1): 9495.

[140]Qiu H, Zhou Z-w, Zhou Y, et al. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma[J]. 2024, 42(16_suppl): 11502-11502.

[141]Qiu H, Yang C, Zhou Z, et al. 1722MO Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)[J]. Annals of Oncology, 2024, 35: S1032.

[142]Liu X, Yu J, Li Y, et al. Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution[J]. Cell Death Dis, 2024, 15(3): 190.

[143]Tao P, Wang Z, Wang J, et al. 241P Single-cell RNA analysis uncovers tumor microenvironment heterogeneity and underlying mechanisms for imatinib resistance in gastrointestinal stromal tumor[J]. Annals of Oncology, 2024, 35: S103.

[144]Wu X, Iwatsuki M, Takaki M, et al. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1[J]. Gastric Cancer, 2024, 27(2): 235-247.

[145]Wu X, Yamashita K, Matsumoto C, et al. YAP acts as an independent prognostic marker and regulates growth and metastasis of gastrointestinal stromal tumors via FBXW7-YAP pathway[J]. Journal of Gastroenterology, 2025, 60(3): 275-284.

[146]Cui Z, Sun H, Gao Z, et al. TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors[J]. Br J Cancer, 2024, 130(4): 526-541.

[147]Li Y, Zhang R, Fu C, et al. Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor[J]. Cancer Lett, 2024, 601: 217149.

[148]Yong WP, Naito Y, Hirano H, et al. 267TiP CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor[J]. Annals of Oncology, 2024, 35: S1504.

[149]Han L, Dai Q, He C, et al. A tetrahedral DNA nanoplatform with ultrasound-triggered biomimetic nanocarriers for targeted siMCM2 delivery and reversal of imatinib resistance in gastrointestinal stromal tumors[J]. Chemical Engineering Journal, 2025, 504: 158843.

[150]Sun X, Lin X, Zhang Q, et al. Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study[J]. 2024, 13(18): e70237.

[151]Wen H, Huang Y, Huang S, et al. The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study[J]. Int J Surg, 2024, 110(4): 2151-2161.

[152]Yang L, Lin T, Gao X, et al. 116P Ripretinib used for preoperative treatment of metastatic gastrointestinal stromal tumor after failure of imatinib therapy[J]. Annals of Oncology, 2024, 35: S1446.

[153]Sun H, Cui Z, Li C, et al. USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition[J]. 2024, 11(34): 2401171.

[154]Heinrich MC, Zhang X, Jones RL, et al. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies[J]. Clin Cancer Res, 2024, 30(4): 719-728.

[155]Dong Z, Zhao X, Zheng H, et al. Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study[J]. EClinicalMedicine, 2024, 73: 102656.

[156]Bertsimas D, Margonis GA, Sujichantararat S, et al. Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study[J]. Lancet Oncol, 2024, 25(8): 1025-1037.

[157]Wang R, Kang W, Liu Z, et al. Head-to-Head Comparison of [(68)Ga]Ga-NOTA-RM26 and [(18)F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study[J]. J Nucl Med, 2025, 66(2): 201-206.

[158]Wu C, Wen F, Lin F, et al. Predictive performance of [18F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT) in evaluating response of recurrent or metastatic gastrointestinal stromal tumors: complementary or alternative to [18F]fluorodeoxyglucose (FDG) PET/CT?[J]. 2024, 2024, 14(8): 5333-5345.

[159].Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin.Endocrinol Metab 2014;99:1915-1942

[160].Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma,paraganglioma, and medullary thyroid cancer. Pancreas 2010;39:775-783.

[161]Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul) 2017;32:152-161.

[162]Turkova H, Prodanov T, Maly M, et al. Characteristics and outcomes of metastatic Sdhb and sporadic pheochromocytoma/paraganglioma: An National Institutes of Health study. Endocr Pract 2016;22:302-314.

[163]King KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 2011;29:4137-4142.

[164]Fishbein L, Merrill S, Fraker DL, et al. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 2013;20:1444-1450.

[165]Pacak K, Jochmanova I, Prodanov T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013;31:1690-1698.

[166]David Taïeb , George B Wanna , Maleeha Ahmad ,et al.(2023). Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.Lancet Diabetes Endocrinol . 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31.

[167]Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of highspecific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 2019;60:623-630.

[168]Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab 2017;102:3278-3287.

[169]Satapathy S, Mittal BR, Bhansali A. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf) 2019;91:718-727.

[170]Tanabe A, Naruse M, Nomura K, et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013;4:103-110.

[171]Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012;118:2804-2812.

[172]Camilo Jimenez , Mouhammed Amir Habra , Matthew T Campbell. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.Lancet Oncol. 2024 May;25(5):658-667.doi: 10.1016/S1470-2045(24)00133-5.Epub 2024 Apr 9.

[173]Eric Baudin , Bernard Goichot , Alfredo Berruti.Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.Lancet.2024Mar16;403(10431):1061-1070. doi:10.1016/S0140-6736(23)02554-0.Epub 2024 Feb 22.

[174]Eric Jonasch , Ian E McCutcheon , Dan S Gombos ,et al.(2018).Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.Lancet Oncol . 2018 Oct ; 19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17.

[175]Aurélie Morin , Judith Goncalves,Sophie Moog ,etal.(2020).TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition.Cell Rep . 2020 Mar 31;30(13):4551-4566.e7.doi: 10.1016/j.celrep.2020.03.022.

[176]Timothy J Walker , Eduardo Reyes-Alvarez , Brandy D Hyndman ,et al.(2024)Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.Elife . 2024 Apr 30:12:RP89100. doi: 10.7554/eLife.89100.

[177]Qianjin Guo, Zi-Ming Cheng, Hector Gonzalez-Cantú ,et al.TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.Cell Rep.2023 Sep 26;42(9):113070.doi: 10.1016/j.celrep.2023.113070. Epub 2023 Sep 1.

[178]Priyanka Gupta , Keehn Strange , Rahul Telange ,et al.(2022). Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer.Cell Rep . 2022 Aug 16;40(7):111218 . doi: 10.1016/j.celrep.2022.111218.

[179]Farooq U, El Alayli A, Duvvuri A, et al. Nonsteroidal Anti-inflammatory Drugs for Chemoprevention in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis[J]. Gastro Hep Adv, 2023, 2(7): 1005-1013.

[180]Tazzari M, Brich S, Tuccitto A, et al. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types[J]. J Immunol Res, 2018, 2018: 5804230.

[181]Shrestha R, Nabavi N, Lin YY, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma[J]. Genome Med, 2019, 11(1): 8.

[182]Braun DA, Bakouny Z, Hirsch L, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma[J]. Nat Rev Clin Oncol, 2021, 18(4): 199-214.

[183]Heinrich MC, Jones RL, George S, et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial[J]. Nat Med, 2024, 30(2): 498-506.

技术支持：乐问医学